This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Robert M. Jeresaty, MD
Saint Francis Hospital and Medical Center Hartford, Conn

JAMA. 1986;255(7):904-905.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

The letters by Drs Romanic, Alves, and Lebow and Ross raise important questions about the management of mitral valve prolapse and are greatly appreciated.

In response to Dr Romanic's comments, I do not believe that the in vitro studies reported by Walsh et al would justify subjecting 5% of the population to antiplatelet therapy, which has its own risks. As I pointed out in my article, because of the high prevalence of mitral valve prolapse and the rare occurrence of cerebral ischemic episodes, antiplatelet therapy is not advocated on a preventive basis in all patients with mitral valve prolapse.^1,2

Dr Alves would favor antiplatelet therapy in women who have mitral valve prolapse and are using oral contraceptive agents and would advocate screening women using oral contraceptives for mitral valve prolapse. To the best of my knowledge, the hypercoagulability caused by oral contraceptives is due to a defect . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?